


Journal Pre-proof

Molecular diagnosis of childhood immune dysregulation, polyendocrinopathy and enteropathy, and implications for clinical management

Sarah K. Baxter, MD PhD, Tom Walsh, PhD, Silvia Casadei, PhD, Mary M. Eckert, BS, Eric J. Allenspach, MD PhD, David Hagin, MD PhD, Gesmar Segundo, MD PhD, Ming K. Lee, PhD, Suleyman Gulsuner, MD PhD, Brian H. Shirts, MD PhD, Kathleen E. Sullivan, MD PhD, Michael D. Keller, MD, Troy R. Torgerson, MD PhD, Mary-Claire King, PhD



PII: S0091-6749(21)00610-2

DOI: <https://doi.org/10.1016/j.jaci.2021.04.005>

Reference: YMAI 15070

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 19 January 2021

Revised Date: 13 March 2021

Accepted Date: 7 April 2021

Please cite this article as: Baxter SK, Walsh T, Casadei S, Eckert MM, Allenspach EJ, Hagin D, Segundo G, Lee MK, Gulsuner S, Shirts BH, Sullivan KE, Keller MD, Torgerson TR, King M-C, Molecular diagnosis of childhood immune dysregulation, polyendocrinopathy and enteropathy, and implications for clinical management, *Journal of Allergy and Clinical Immunology* (2021), doi: <https://doi.org/10.1016/j.jaci.2021.04.005>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.

Molecular diagnosis of childhood immune dysregulation, polyendocrinopathy and enteropathy, and implications for clinical management

Sarah K Baxter MD PhD^{1,2,3}, Tom Walsh PhD³, Silvia Casadei PhD³, Mary M Eckert BS², Eric J Allenspach MD PhD^{1,2}, David Hagin MD PhD^{2,4}, Gesmar Segundo MD PhD⁵, Ming K Lee PhD³, Suleyman Gulsuner MD PhD³, Brian H Shirts MD PhD⁶, Kathleen E Sullivan MD PhD⁷, Michael D Keller MD⁸, Troy R. Torgerson MD PhD^{1,2*}, Mary-Claire King PhD^{3^}

¹ Department of Pediatrics (Pediatric Rheumatology), University of Washington, Seattle WA

² Seattle Children's Hospital and Research Institute, Seattle WA

³ Department of Medicine (Medical Genetics) and Department of Genome Sciences, University of Washington, Seattle WA

⁴ Allergy and Clinical Immunology Unit, Department of Medicine, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, University of Tel Aviv, ISRAEL

⁵ Department of Pediatrics (Allergy and Immunology), Universidade Federal de Uberlandia, Minas Gerais, BRAZIL

⁶ Department of Laboratory Medicine and Pathology, University of Washington, Seattle WA

⁷ Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, PA

⁸ Division of Allergy and Immunology, Children's National Hospital, Washington, DC

* Current address: Allen Institute for Immunology, Seattle WA

^ Corresponding author: Mary-Claire King, University of Washington, Health Sciences K-160,
1959 NE Pacific Street, Seattle WA 98195-7720; phone 206.616.4294, fax 206.616.4295; email
mcking@uw.edu

Funding: NIH R35CA197458 (M.C.K) and King Lab Gift Fund

Disclosures: Tom Walsh PhD is a consultant for Color Genomics. Troy Torgerson MD PhD is
currently employed by the Allen Institute for Immunology, Seattle. The rest of the authors
declare that they have no relevant conflicts of interest.

Background. Most patients with childhood-onset immune dysregulation, polyendocrinopathy and enteropathy have no genetic diagnosis for their illness. These patients may undergo empirical immunosuppressive treatment with highly variable outcomes.

Objective. To determine the genetic basis of disease in patients referred with “IPEX-like” disease, but with no mutation in *FOXP3*; then to assess consequences of genetic diagnoses for clinical management.

Methods. Genomic DNA was sequenced using a panel of 462 genes implicated in inborn errors of immunity. Candidate mutations were characterized by genomic, transcriptional, and (for some) protein analysis.

Results: Of 123 patients with *FOXP3*-negative IPEX-like disease, 48 (39%) carried damaging germline mutations in one of 27 genes including *AIRE*, *BACH2*, *BCL11B*, *CARD11*, *CARD14*, *CTLA4*, *IRF2BP2*, *ITCH*, *JAK1*, *KMT2D*, *LRBA*, *MYO5B*, *NFKB1*, *NLRC4*, *POLA1*, *POMP*, *RAG1*, *SH2D1A*, *SKIV2L*, *STAT1*, *STAT3*, *TNFAIP3*, *TNFRSF6/FAS*, *TNRSF13B/TACI*, *TOM1*, *TTC37*, and *XIAP*. Many of these had not been previously associated with an IPEX-like diagnosis. For 42 of the 48 patients with genetic diagnoses, knowing the critical gene may have altered therapeutic management, including recommendations for targeted treatments and for or against hematopoietic cell transplantation.

Conclusion: Many childhood disorders now bundled as “IPEX-like” disease are caused by individually rare, severe mutations in immune regulation genes. Most genetic diagnoses of these conditions yield clinically actionable findings. Barriers are lack of testing or lack of repeat testing if older technologies failed to provide a diagnosis.

Clinical Implication: Pediatric immune dysregulation would benefit from a genetics-first approach to diagnosis: for >80% of these patients with genetic diagnoses, the genetic information offers critical guidance to clinical management.

CAPSULE SUMMARY

Immune dysregulation, polyendocrinopathy or enteropathy in many pediatric patients results from a mutation with severe clinical effect. Identification of these causal mutations enables treatment based on genotype, supporting a genetics-first approach to diagnosis.

KEY WORDS

Immune dysregulation; molecular diagnosis; genetics; sequencing; pediatric; precision medicine; autoimmunity; inborn errors of immunity; primary immunodeficiency disorders

ABBREVIATIONS

IPEX, Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked; CNV, copy number variant; IPE, Immune dysregulation, polyendocrinopathy, enteropathy; IUIS, International Union of Immunological Societies; UW, University of Washington; SCH, Seattle Children's Hospital; HCT, hematopoietic cell transplantation; PBMC, peripheral blood mononuclear cell; ACMG, American College of Medical Genetics; THE, trichohepatoenteric

INTRODUCTION

Clinical presentations of immune dysregulation in children are notoriously complex^{1,2,3}. Genetic diagnoses can help disentangle this complexity and can also guide clinical management of these patients, suggesting targeted therapies or prompting hematopoietic cell transplantation (HCT)⁴. Despite excellent studies revealing genetic causes of primary immunodeficiency diseases⁵, there are as yet no widely accepted recommendations for genetic testing of pediatric patients with immune dysregulation. Even now, a decade after next-generation sequencing became widespread, genetic testing for inborn errors of immunity often proceeds only following functional testing and in targeted panels, with the choice of gene frequently based on phenotype and serology. This approach misses genetic diagnoses of a large proportion of patients.

Among inborn errors of immunity, IPEX (Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked) syndrome, caused by mutations in *FOXP3*, a lineage-defining gene in regulatory T cells, is a prototype of disorders affecting regulation of immune responses^{6,7}. IPEX manifests most commonly with severe diarrhea, dermatitis, and autoimmune endocrinopathies such as type 1 diabetes or thyroid disease⁸. However, these clinical features are widespread in pediatric diseases of immune dysregulation, and many patients with these symptoms have no mutation in *FOXP3*. These patients have been termed “IPEX-like,” a distinction that is clinically significant, because patients with *FOXP3* mutations usually undergo HCT⁹, whereas patients with IPEX-like syndrome are generally monitored and treated with immunomodulatory treatments aimed at the affected organ system. Patients with IPEX-like syndrome receive transplantation only if their disease progresses and becomes life-threatening. If HCT is ultimately undertaken, the delay in treatment can result in higher morbidity and mortality.

100

101 The scope, prevalence, and distribution of genes and mutations responsible for *FOXP3*-negative
102 pediatric immune dysregulation, polyendocrinopathy or enteropathy (IPE) are not known. The
103 goal of this project was to determine the underlying genetic causes of these conditions in
104 pediatric patients with no mutation in *FOXP3*, to assess the diagnostic yield of genetic testing in
105 these patients, and to evaluate the implications of genetic diagnosis for treatment.

METHODS

Study subjects

The study was approved by the institutional review boards of Seattle Children's Hospital (SCH) and the University of Washington (UW). Patients were eligible for the study if referred to SCH with clinical signs suggestive of IPEX, and hence for genetic analysis of *FOXP3*, but with no *FOXP3* mutation identified. DNA was available for 123 such patients.

Gene panel development

We designed an oligonucleotide-based sequencing panel encompassing the coding exons, 5' and 3' untranslated regions, and flanking intronic regions of 462 known and candidate genes for immune-mediated disease (Table EI). Genes were chosen from the classification of immune genes by the International Union of Immunological Societies (IUIS)¹⁰, and by review of the literature and consensus expert opinion of colleagues from immunology, rheumatology, and genetics. Of the 462 genes, 337 genes harbor mutations leading to inborn errors of immunity in humans; the other 125 genes are involved in immune tolerance, many with compelling murine models. Total length of the targeted genomic region was 1.5 MB. The panel enables simultaneous identification of single base pair mutations, small insertions and deletions, and exon-impacting copy number variants (CNVs) for all targeted genes. The panel was validated by blinded analysis of 33 patients with independently identified mutations. All genotypes were concordant with previous results. In addition to its research use, the panel is now in clinical use by the UW Department of Laboratory Medicine¹¹.

Genomics

Genomic DNA was isolated from whole blood, from peripheral blood mononuclear cells (PBMCs), or from expanded PBMCs. For each sample, 500-750ng DNA was captured using the oligonucleotide panel. Molecular barcodes were added after hybridization, and 32-48 samples were multiplexed and sequenced in a single flow-cell on an Illumina HiSeq2500 instrument to obtain 100bp paired-end reads at >400x median coverage. Identification of variants was carried out as previously described¹². Copy number variants (CNVs) were confirmed by TaqMan analysis and breakpoints identified by whole genome sequencing, also as described¹².

Interpretation of genetic variants

Variant interpretation was based on the guidelines of the American College of Medical Genetics (ACMG)¹³, as applied to conditions of pediatric immune dysregulation. As described above, the challenges of these conditions are, on the one hand, phenotypes defined by an exceptionally wide range of clinical presentations and, on the other hand, candidate genes with an exceptionally wide range of biological functions, with no straightforward alignment of phenotypes and genes. For each patient, candidate variants were evaluated by several criteria and experiments: by *in silico* predictive tools; by published functional studies; by similarities of clinical presentations of our patient with any patients previously reported with mutations in the same gene; by transcriptional analysis in our lab when appropriate and feasible¹⁴; and by testing for *de novo* inheritance, if DNA from parents could be obtained. For each variant that we reported as pathogenic, likely pathogenic, or of unknown significance (VUS), we provided a narrative explanation of published evidence and of experiments carried out in our lab, as well as reporting *in silico* predictions and prior classification by ClinVar¹⁵. The VUS classification was used

151 sparingly, only for mutations with plausible but uncertain links to the patient's phenotype, for
152 which further functional or genetic studies could add to evidence for or against causality.

RESULTS

Genetic diagnoses

Demographic and clinical features of the cohort. Demographic and clinical characteristics of the 123 patients are shown in Table I. Most patients were male, consistent with original referral for X-linked IPEX syndrome. Patients were referred by physicians from six continents and represented a wide variety of ancestral populations, identified by self-report and by ancestral SNPs¹⁶. Clinical diagnoses were heterogeneous, including enteropathy, dermatitis, autoimmune hemolytic anemia, type I diabetes, and other autoimmune conditions.

Genomic sequencing. Genomic analysis of DNA samples from the 123 patients yielded median coverage across the targeted region of 406X, with 95.9% of targeted bases having >40X coverage and 99.1% of targeted bases having >8X coverage. This depth of coverage enabled identification of point mutations and small insertions and deletions in coding or regulatory regions and exon-impacting CNVs.

Frequencies and features of genetic diagnoses. Genomic analysis yielded genetic diagnoses for 39% of patients (48 of 123), involving 27 different genes (Table II). All variants considered pathogenic, likely pathogenic, or of unknown significance but warranting further study, are indicated in Table III, with evidence bearing on causality for the child's phenotype. Of the 28 different conditions in the 48 patients with genetic diagnoses, 19 conditions were inherited as autosomal dominant, 7 as autosomal recessive, and 2 as X-linked recessive. Damaging mutations included truncating, splice altering, and missense mutations, each private or extremely rare (Table III). Five patients carried multi-kilobase genomic deletions or amplifications in single

genes (Figs E1, E2). Of the 56 different variants contributing to these 48 genetic diagnoses, 36 appeared for the first time in a patient in this series and 20 had been previously reported^{Error!} (Table III). Of the 58 reported variants, 52 were classified as pathogenic or likely pathogenic and 4 as VUS with recommendation for further functional analysis (Table III). Proportions of patients with genetic diagnoses were similar for males (37/94, or 39%) and for females (11/29, or 38%). Average age at referral for patients with a genetic diagnosis was 6.2y and for patients with no genetic diagnosis was 6.6y.

Biological functions of genes mutant in patients

Mutant genes in the IUIS classification system. Genes responsible for patients' diagnoses are involved in both adaptive and immune response (Table II), and in biological functions including signaling, cell differentiation, apoptosis, debris handling, and epithelial integrity (Figure 1). The 27 genes appeared in multiple categories of the phenotypic classification system for inborn errors of immunity of the International Union of Immunological Societies' (IUIS) (Table II)¹⁰. Causal genes in the IUIS Immune Dysregulation category would be expected, given original clinical suspicion for IPEX. However, an equal number of genetic diagnoses were due to genes in other IUIS phenotypic categories, including Autoinflammatory Disorders, Antibody Deficiencies, Combined Immunodeficiencies, and Defects in Intrinsic and Innate Immunity. Most of the 27 genes were not previously reported in the context of "IPEX-like" disease.

For some genes, the mutations of these patients provide additional support for the role of the genes in IPE (Tables II, III). For example, somatic mutations in the *JAK1* kinase are common in tumors, but a germline mutation in *JAK1* has previously been documented in only one family¹⁷.

Patients S66, S67, and S170, with severe IPE phenotypes, carry three different damaging mutations in *JAK1*, strongly supporting a role for *JAK1* germline mutations in IPE (Figure S2). Similarly, *IRF2BP2* encodes a transcriptional regulator of type I interferon and has a well-documented role in immune regulation, angiogenesis, and apoptosis^{18,19}, but a germline mutation in *IRF2BP2* has been previously documented in only one family²⁰. Patient S125, with a similar phenotype to the previously reported patient, carries a *de novo* damaging mutation in *IRF2BP2*, supporting a role for this gene in IPE.

Two genes responsible for diagnoses of our patients were not previously included in the IUIS classification. *TOM1* encodes a protein of endocytosis, with a missense mutation previously reported in a family with autosomal dominant immune dysregulation and impaired autophagy²¹. Patient S15, with a severe IPE phenotype, is heterozygous for a *TOM1* splice mutation that produces a stable product lacking the vesicular trafficking domain, so likely yielding a dominant negative effect (Figure E3). Mutations in *MYO5B* are well documented in patients with microvillus inclusion disease²². Like patient SDH, patients with *MYO5B* deficiency can have extraintestinal manifestations, including hematuria, lung disease, and increased susceptibility to infection²³.

Immune regulation and dysmorphology. For four patients, immune dysregulation appeared in combination with dysmorphology. Three patients with mildly dysmorphic features harbored mutations in *TTC37* or *SKIV2L*, both of which are responsible for tricho-hepato-enteric (THE) syndrome^{24,25}. One patient, with a splice mutation in *KMT2D*, presented with features of Kabuki syndrome in addition to autoimmune dysregulation and severe enteropathy, both of which are

rare but reported features of Kabuki syndrome^{26,27}. Genetic analysis is quite frequently undertaken for patients with dysmorphic features. However, for several patients with mutations in dysmorphism genes, these features were subtle and not recognized until after the genetic diagnosis.

Genetic diagnoses and treatment

For 42 of the 48 patients with genetic diagnoses, knowing the critical gene could have guided treatment (Figure 2). Specific management implications for each patient with a genetic diagnosis are indicated in Table EII. Some patients for whom the causal gene was identified could have been treated with appropriately targeted immune modulatory drugs. Patients whose genetic diagnoses suggested life-limiting disease may have been considered for HCT early in their disease course. Conversely, patients with genetic diseases having less severe outcomes or no effective therapies may have avoided high-risk treatments.

Targeted therapeutics. For 25 patients, genetic diagnoses suggested specific targeted therapies. For example, abatacept, a CTLA-Ig fusion protein, has been reported to be an effective targeted therapy for patients with *CTLA4* haploinsufficiency or *LRBA* deficiency²⁸. JAK inhibitors have been shown to be effective in patients with *JAK1*, *STAT1*, or *STAT3* gain-of-function mutations²⁹. Patients with *NLR4* gain-of-function mutations have been treated successfully in preliminary studies with recombinant IL-18-binding protein³⁰, and a clinical trial is underway evaluating this treatment in patients with *XIAP* mutations³¹. Patients with *CARD14* and *TNFAIP3* mutations often respond to TNF-alpha inhibitors and to IL12/IL23 inhibitors^{32,33}.

Screening. For 29 patients, genetic diagnoses would have altered recommendations for screening. Loss of function mutations in *STAT3*, *FAS*, and *SH2D1A* predispose to lymphoma, and gain of function mutations in *STAT3* predispose to leukemia³⁴. Patients with *CTLA4* haploinsufficiency and *LRBA* deficiency also appear to be at a higher risk for cancer^{35,36}. In our series, two of four patients with *LRBA* deficiency developed malignancies: patient S45 died at age 16 from gastric adenocarcinoma, and patient S14 developed lymphoma at age 3. Patients with mutations in *AIRE*, *RAG1* and *NFKB1* can develop a broad range of autoimmune phenomena that call for regular thyroid, blood, liver, renal, and pulmonary screening^{2,37,38}. Patients with *STAT3* mutations should undergo pulmonary screening³⁹, and although there are limited cases reported, current evidence also supports pulmonary screening for patients with mutations in *BACH2*, *ITCH* and *TOM1*^{21,40,41}. Patients with *POLAI* deficiency (figure E4) should undergo regular ophthalmologic exams, given the risk of sterile inflammation leading to cataracts, scarring and blindness⁴².

Hematopoietic cell transplantation (HCT). For 18 patients, genetic diagnoses represent potential indications for HCT. The 8 patients with *CTLA4* haploinsufficiency and *LRBA* deficiency would be strongly considered for HCT given the increasing evidence of high morbidity and mortality in these diseases. For example, patient S88 developed inflammatory brain lesions while on abatacept; because he had failed appropriate targeted therapy and had a genetic diagnosis, he underwent HCT. Patients with mutations in *XIAP*, *RAG1*, and *SH2D1A* are also frequently considered for early HCT^{43,44,45}. Patient S21, who had hypogammaglobulinemia and autoimmune enteropathy beginning in early childhood, was referred for genetic testing at age

16y. She was found to have compound heterozygous *RAG1* mutations, often considered an indication for HCT. She died at age 16 from a fungal infection prior to genetic diagnosis.

Genetic diagnosis can benefit patients even if gene-specific therapeutic guidelines are not yet available. For instance, severe childhood illness may lead physicians to attempt HCT in the absence of a genetic diagnosis. If genetic diagnosis reveals the cause of disease to be a gene of the hematopoietic system, bone marrow transplantation is more likely to be effective.

Conversely, for the 6 patients with mutations in *MYO5B*, *TTC37*, *SKIV2L*, and *CARD14*, HCT would be unlikely to ameliorate disease, since these include epithelial defects that do not respond to HCT⁴⁶. Moreover, a genetic diagnosis can be crucial to guide diagnosis in patients' relatives.

For instance, patient S92, with *CTLA4* haploinsufficiency, underwent HCT due to the severity of his disease despite lacking a genetic diagnosis. He now has an infant son who can be screened for the same mutation.

DISCUSSION

Enabling precision medicine for children with immune dysregulation, polyendocrinopathy or enteropathy requires embracing genetic heterogeneity. That is, despite all patients in this project being referred for the same clinical concern (IPEX), many different genes were responsible for their illnesses, including some genes known to cause IPEX-like disease and others not previously associated with this syndrome. The diversity of IUIS phenotypes among these patients highlights the difficulty of inferring genotype from phenotype and the value of comprehensive genomic analysis early in the course of disease.

This genetic heterogeneity reflects the clinical reality that the features of childhood immune disorders are widely encountered and overlapping. The search for a genetic cause cannot realistically be based only on clinical phenotype, because immune dysregulation conditions have ill-defined phenotypic boundaries and can be due to any of multiple different genes. A genetics-first paradigm avoids unhelpful classifications that may lead to errors in diagnosis or therapy. To assist this practice, we suggest that when a causal link between gene and phenotype is established, the gene responsible for an immune disorder be included in its name (e.g. *LRBA* immunodeficiency). Diagnoses impact treatment options and define cohorts for scientific studies. By including the responsible gene in the name of each disease, clinicians can avoid ambiguity and immediately access treatments most promising for the patient.

Genetic testing platforms vary widely in capacity and limitations⁴⁷. Given rapidly improving technology, it is important both to seek early genetic diagnosis and to re-evaluate if original results are negative. Sequencing to high coverage and including critical intronic and regulatory

regions among the targets greatly increases detection sensitivity for copy number variants (CNVs), which for our patients represented 10% of all mutations. CNVs were particularly frequent in *LRBA* and represent a growing class of defects for which genetic diagnosis dictates targeted therapy. Custom-designed gene panels detect this class of mutations, but most exome sequencing does not. In practice, most commercial clinical sequencing is now exome sequencing, with “gene panels” in fact simply exome sequence data with only a subset of genes reported to the physician. Approximately 10% of the mutations of our patients would have been missed by exome sequencing.

If genetic disease remains a consideration despite a negative genetic test, it is worth considering more complete and current genomic analysis. False negatives on genetic tests can result from coverage that is inadequate to detect structural variants, from incorrect variant interpretation, from limitations in knowledge of gene function and hence of pathogenic variants, or from lab error. Errors of variant interpretation can be subtle and include failure to detect effects on transcription caused by mutations that do not alter amino acid sequence, failure to detect mutations at sites other than exon-intron boundaries that alter splicing, failure to distinguish variation in true genes from variation in pseudogenes, and so on. The pace of gene discovery, knowledge about individual genes, knowledge of classes of cryptic mutations, and technological advance all support additional genetic testing as platforms improve. Immunologists will likely find it useful to consult with academic centers to interpret increasingly complex genetic information. Conversely, clinically well-characterized patients will very greatly contribute to functional analysis of new mutations.

In our experience, negative results from tests of single genes or narrow panels have almost no value, and furthermore may impair the ability of clinicians to do follow-up testing due to insurance limitations. The solution is for the first genetic test to include as many genes and as many classes of mutations as possible, either from a large gene panel or from whole exome sequencing.

This project had several limitations, largely as the result of some patients being originally referred several years ago. First, for some patients, clinical information was limited and referring physicians were no longer available. Second, only probands were available for initial analysis, although a few families were re-contacted through the referring providers. Analysis of a child and both parents is critical to identifying *de novo* mutations, an important part of genetic diagnosis⁴⁸. Analysis of the complete patient-parent-parent trio is particularly important in the evaluation of mutations in genes such as CTLA4. Severe mutations in CTLA4 can lead to severe phenotypes, as in our patients (Tables II and III), but in some families, mutations in CTLA4 have been identified in relatives with no, or late-onset, clinical signs^{49,50}. It is possible that *CTLA4* mutations with severe, early onset phenotypes are *de novo* in affected children, but this speculation can only be tested with DNA from parents. Both these limitations reduced the number of genetic diagnoses in which we had confidence.

A third limitation was that our gene-panel sequencing strategy detected all mutations in coding sequence and all gene-impacting copy number variants but did not detect mutations in distant non-coding genomic regions. Such distant non-coding mutations would be revealed by whole genome sequencing. The cost of whole genome sequencing is rapidly

decreasing, but the cost of interpreting non-coding variants in whole genome sequence is very high. Insurance reimbursement is the practical limitation to applying whole genome sequencing to genetic diagnosis to these or other complex conditions.

Despite these limitations, the yield of reportable mutations among the children in this series was quite high (39%). Analysis of an active clinical population, with patient-parent-parent trios available for testing, would yield more solved cases with correspondingly greater benefit for management.

In conclusion, genetic diagnoses of children with immune dysregulation, polyendocrinopathy and enteropathy, but no mutation in *FOXP3*, revealed a wide array of clinical immune diseases and disruption of a wide array of biological pathways. More than 80% of genetic diagnoses were clinically actionable. We suggest that these results support a “genetics first” approach for patients with severe, early-onset immune dysregulation. We propose that all patients with childhood-onset immune dysregulation undergo comprehensive genomic analysis, rather than single-gene testing or no genetic testing at all. Treatments targeting immune pathways are rapidly advancing. To harness the promise of these treatments, it is critical to fully exploit genetic testing.

367 **REFERENCES**

-
- ¹ Leiding JW, Forbes LR. Mechanism-based precision therapy for the treatment of primary immunodeficiency and primary immunodysregulatory diseases. *J Allergy Clin Immunol Pract.* 2019;7(3):761–773. DOI: 10.1016/j.jaip.2018.12.017
- ² Farmer JR, Foldvari Z, Ujhazi B, De Ravin SS, Chen K, Bleesing JJH, et al. Outcomes and treatment strategies for autoimmunity and hyperinflammation in patients with RAG deficiency. *J Allergy Clin Immunol Pract.* 2019;7(6):1970-1985. DOI: 10.1016/j.jaip.2019.02.038.
- ³ Gámez-Díaz L, August D, Stepensky P, Revel-Vilk S, Seidel MG, Noriko M, et al. The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency. *J Allergy Clin Immunol.* 2016;137(1):223-230. doi: 10.1016/j.jaci.2015.09.025.
- ⁴ Delmonte OM, Notarangelo LD. Targeted therapy with biologicals and small molecules in primary immunodeficiencies. *Med Princ Pract.* 2020;29(2):101–112. doi: 10.1159/000503997.
- ⁵ Stray-Pedersen A, Sorte HS, Samarakoon P, Gambin T, Chinn IK, Coban Akdemir ZH, et al. Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders. *J Allergy Clin Immunol.* 2017;139:232-245. doi: 10.1016/j.jaci.2016.05.042
- ⁶ Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. *Nat Genet.* 2001;27(1):18-20. doi: 10.1038/83707.
- ⁷ Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. *Nat Genet.* 2001;27(1):20-21. doi: 10.1038/83713.
- ⁸ Barzaghi F, Amaya Hernandez LC, Neven B, Ricci S, Kucuk ZY, Bleesing JJ, et al. Primary Immune Deficiency Treatment Consortium (PIDTC) and the Inborn Errors Working Party

(IEWP) of the European Society for Blood and Marrow Transplantation (EBMT). Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. *J Allergy Clin Immunol* 2018;141:1036-1049. doi: 10.1016/j.jaci.2017.10.041.

⁹ Burroughs LM, Torgerson TR, Storb R, Carpenter PA, Rawlings DJ, Sanders J, et al. Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. *J Allergy Clin Immunol* 2010;126:1000-5. doi: 10.1016/j.jaci.2010.05.021.

¹⁰ Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. *J Clin Immunol*. 2020;40(1):24-64. doi: 10.1007/s10875-019-00737-x.

¹¹ University of Washington Department of Laboratory Medicine and Pathology: <https://testguide.labmed.uw.edu/public/view/IMD>

¹² Abu Rayyan A, Kamal L, Casadei S, Brownstein Z, Zahdeh F, Shahin H, et al. Genomic analysis of inherited hearing loss in the Palestinian population. *Proc Natl Acad Sci USA* 2020;117(33):20070-6. doi: 10.1073/pnas.2009628117.

¹³ Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants. *Genet Med*. 2015;17(5):405-24. doi: 10.1038/gim.2015.30.

¹⁴ Casadei S, Gulsuner S, Shirts BH, Mandell JB, Kortbawi HM, Norquist BS, et al. Characterization of splice-altering mutations in inherited predisposition to cancer. *Proc Natl Acad Sci USA*. 2019;116(52):26798-807. doi: 10.1073/pnas.1915608116.

-
- ¹⁵ ClinVar: <http://www.ncbi.nlm.nih.gov/clinvar/>
- ¹⁶ Gulsuner S, Stein DJ, Susser ES, Sibeko G, Pretorius A, Walsh T, et al. Genetics of schizophrenia in the South African Xhosa. *Science*. 2020;367(6477):569-73. doi: 10.1126/science.aay8833.
- ¹⁷ Del Bel KL, Ragotte RJ, Saferali A, Lee S, Vercauteren SM, Mostafavi SA, et al. JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome. *J Allergy Clin Immunol*. 2017;139(6):2016-2020. doi: 10.1016/j.jaci.2016.12.957.
- ¹⁸ Chen HH, Keyhanian K, Zhou X, Vilmundarson RO, Almontashiri NA, Cruz SA, et al. IRF2BP2 reduces macrophage inflammation and susceptibility to atherosclerosis. *Circ Res* 2015;117:671-683. doi: 10.1161/CIRCRESAHA.114.305777.
- ¹⁹ Ramalho-Oliveira R, Oliveira-Vieira B, Viola JPB. IRF2BP2: A new player in the regulation of cell homeostasis. *J Leukoc Biol* 106:717-723. doi: 10.1002/JLB.MR1218-507R.
- ²⁰ Keller MD, Pandey R, Li D, Glessner J, Tian L, Henrickson SE, et al. Mutation in IRF2BP2 is responsible for a familial form of common variable immunodeficiency disorder. *J Allergy Clin Immunol*. 2016;138(2):544-550. doi: 10.1016/j.jaci.2016.01.018.
- ²¹ Keskitalo S, Haapaniemi EM, Glumoff V, Liu X, Lehtinen V, Fogarty C, et al. Dominant TOM1 mutation associated with combined immunodeficiency and autoimmune disease. *NPJ Genom Med*. 2019;4:14. doi: 10.1038/s41525-019-0088-5.
- ²² Müller T, Hess MW, Schiefermeier N, Pfaller K, Ebner HL, Heinz-Erian P, et al. MYO5B mutations cause microvillus inclusion disease and disrupt epithelial cell polarity. *Nat Genet*. 2008;40(10):1163-1165. doi: 10.1038/ng.225.
- ²³ Siahianidou T, Koutsounaki E, Skiathitou AV, Stefanaki K, Marinos E, Panajiotou I, et al. Extraintestinal manifestations in an infant with microvillus inclusion disease: complications or

features of the disease?. *Eur J Pediatr*. 2013;172(9):1271-1275. doi: 10.1007/s00431-013-1948-0.

²⁴ Fabre A, Martinez-Vinson C, Roquelaure B, Missirian C, André N, Breton A, et al. Novel mutations in TTC37 associated with tricho-hepato-enteric syndrome. *Hum Mutat*. 2011;32(3):277–281. doi: 10.1002/humu.21420.

²⁵ Fabre A, Charroux B, Martinez-Vinson C, Roquelaure B, Odul E, Sayar E, et al. SKIV2L mutations cause syndromic diarrhea, or trichohepatoenteric syndrome. *Am J Hum Genet*. 2012;90(4):689–692. doi: 10.1016/j.ajhg.2012.02.009.

²⁶ Lindsley AW, Saal HM, Burrow TA, Hopkin RJ, Shchelochkov O, Khandelwal P, et al. Defects of B-cell terminal differentiation in patients with type-1 Kabuki syndrome. *J Allergy Clin Immunol*. 2016;137(1):179–187. doi: 10.1016/j.jaci.2015.06.002.

²⁷ Wang YR, Xu NX, Wang J, Wang XM. Kabuki syndrome: review of the clinical features, diagnosis and epigenetic mechanisms. *World J Pediatr*. 2019;15(6):528–535. doi: 10.1007/s12519-019-00309-4.

²⁸ Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. *J Allergy Clin Immunol*. 2018;142(6):1932-1946. doi: 10.1016/j.jaci.2018.02.055.

²⁹ Delmonte OM, Notarangelo LD. Targeted therapy with biologicals and small molecules in primary immunodeficiencies. *Med Princ Pract*. 2020;29(2):101-112. doi: 10.1159/000503997.

³⁰ Canna SW, Girard C, Malle L, de Jesus A, Romberg N, Kelsen J, et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. *J Allergy Clin Immunol*. 2017;139(5):1698-1701. doi: 10.1016/j.jaci.2016.10.022.

³¹ ClinicalTrials.gov: <https://clinicaltrials.gov/ct2/show/NCT03113760>

- ³² Craiglow BG, Boyden LM, Hu R, Virtanen M, Su J, Rodriguez G, et al. CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris. *J Am Acad Dermatol*. 2018;79(3):487-494. doi: 10.1016/j.jaad.2018.02.034.
- ³³ Kadowaki T, Ohnishi H, Kawamoto N, Hori T, Nishimura K, Kobayashi C, et al. Haploinsufficiency of A20 causes autoinflammatory and autoimmune disorders. *J Allergy Clin Immunol*. 2018;141(4):1485- 1488. doi: 10.1016/j.jaci.2017.10.039.
- ³⁴ Chandrasekaran P, Zimmerman O, Paulson M, Sampaio EP, Freeman AF, Sowerwine KJ, et al. Distinct mutations at the same positions of STAT3 cause either loss or gain of function. *J Allergy Clin Immunol*. 2016;138(4):1222-1224.e2. doi: 10.1016/j.jaci.2016.05.007.
- ³⁵ Habibi S, Zaki-Dizaji M, Rafiemanesh H, Lo B, Jamee M, Gámez-Díaz L, et al. Clinical, immunologic, and molecular spectrum of patients with lps-responsive beige-like anchor protein deficiency: a systematic review. *J Allergy Clin Immunol Pract*. 2019;7(7):2379–2386. doi: 10.1016/j.jaip.2019.04.011.
- ³⁶ Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. *J Allergy Clin Immunol*. 2018;142(6):1932-1946. doi: 10.1016/j.jaci.2018.02.055.
- ³⁷ Constantine GM, Lionakis MS. Lessons from primary immunodeficiencies: Autoimmune regulator and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. *Immunol Rev*. 2019;287(1):103-120. doi: 10.1111/imr.12714.
- ³⁸ Tuijnenburg P, Lango Allen H, Burns SO, Greene D, Jansen MH, Staples E, et al. Loss-of-function nuclear factor κ B subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans. *J Allergy Clin Immunol*. 2018;142(4):1285-1296. doi: 10.1016/j.jaci.2018.01.039.

- ³⁹ Fabre A, Marchal S, Barlogis V, Mari B, Barbry P, Rohrlisch PS, et al. Clinical Aspects of STAT3 Gain-of-Function Germline Mutations: A Systematic Review. *J Allergy Clin Immunol Pract.* 2019;7(6):1958-1969.e9. Fabre A, Marchal S, Barlogis V, Mari B, Barbry P, Rohrlisch PS,
- ⁴⁰ Afzali B, Grönholm J, Vandrovcova J, O'Brien C, Sun HW, Vanderleyden I, et al. BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency. *Nat Immunol.* 2017;18(7):813-823. doi: 10.1038/ni.3753.
- ⁴¹ Lohr NJ, Molleston JP, Strauss KA, Torres-Martinez W, Sherman EA, Squires RH, et al. Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease. *Am J Hum Genet* 2010;86:447-453. doi: 10.1016/j.ajhg.2010.01.028.
- ⁴² Starokadomskyy P, Wilton KM, Krzewski K, Lopez A, Sifuentes-Dominguez L, Overlee B, et al. NK cell defects in X-linked pigmentary reticulate disorder. *JCI Insight.* 2019;4(21):e125688. doi: 10.1172/jci.insight.125688.
- ⁴³ Ono S, Okano T, Hoshino A, Yanagimachi M, Hamamoto K, Nakazawa Y, et al. Hematopoietic stem cell transplantation for XIAP deficiency in Japan. *J Clin Immunol.* 2017;37(1):85-91. doi: 10.1007/s10875-016-0348-4.
- ⁴⁴ Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis. *Blood.* 2020;135(16):1332-1343. doi: 10.1182/blood.2019000936.
- ⁴⁵ Farmer JR, Foldvari Z, Ujhazi B, De Ravin SS, Chen K, Bleesing JJH, et al. Outcomes and treatment strategies for autoimmunity and hyperinflammation in patients with RAG deficiency. *J Allergy Clin Immunol Pract.* 2019;7(6):1970-1985.e4. doi: 10.1016/j.jaip.2019.02.038.
- ⁴⁶ Fabre A, Bourgeois P, Coste ME, Roman C, Barlogis V, Badens C. Management of syndromic diarrhea/tricho-hepato-enteric syndrome: A review of the literature. *Intractable Rare Dis Res.* 2017;6(3):152-157. doi: 10.5582/iridr.2017.01040.

- ⁴⁷ Heimall JR, Hagin D, Hajjar J, Henrickson SE, Hernandez-Trujillo HS, Tan Y, et al. Use of genetic testing for primary immunodeficiency patients. *J Clin Immunol*. 2018;38(3):320–329. doi: 10.1007/s10875-018-0489-8.
- ⁴⁸ Baxter SK, King M-C. A time to sequence. *JAMA Pediatr* 2017;171(12):e173435. doi: 10.1001/jamapediatrics.2017.3435.
- ⁴⁹ Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. *Nat Med*. 2014;20(12):1410-1416. doi: 10.1038/nm.3746.
- ⁵⁰ Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. *J Allergy Clin Immunol*. 2018;142(6):1932-1946. doi: 10.1016/j.jaci.2018.02.055.

FIGURE LEGENDS

Figure 1: Genes responsible for childhood immune dysregulation, polyendocrinopathy, and enteropathy. Genes responsible for childhood IPE in 48 patients by principal biological function, based on literature review and Gene Ontology annotation. Genes may act primarily within the adaptive arm of the immune system (blue arc), the innate arm (maroon arc), or both.

Figure 2: IPE disease management recommendations based on genetic diagnoses.

Recommendations for therapy for each gene are presented in supplementary Table EII.

Percentages add to more than 100%, because for some patients, more than one recommendation was available. HCT is hematopoietic cell transplant.

TABLES

Table I. Characteristics of patients referred to Seattle Children's Hospital for genetic testing for *FOXP3*, with negative results.

Table II. Genetic diagnoses with phenotypic classifications of the International Union of Immunological Societies (IUIS)

Table III. Variants classified as pathogenic, likely pathogenic, or VUS-warranting-additional-analysis, with evidence bearing on causality

SUPPLEMENTARY TABLES

Table EI. Genes included in the panel

Table EII. Recommendations for therapy, gene by gene

Figure 1




Figure 2







Figure E1**Figure E1A, E1B. Mutations in *LRBA* in patients S14, S129, and S88**

A. Copy number mutations (CNVs) in patients S14, S129, and S88. Red elements on the *LRBA* genomic plots indicate deleted genomic regions. Minimal deletions are: exons 3-4, chr4:151,792,136 – 151,794,482 for S14; exon 2 including translation start, chr4:151,935,548 – 151,935,625 for S129; and exons 36-37, chr4:151,599,677 – 151,678,661 for S88. Each patient was compound heterozygous for a second, point mutation in *LRBA* (Table S2).

B. Patient S88 developed chronic interstitial lung disease, diagnosed at age 11 (top panel). He was started on abatacept with symptomatic improvement in his lung disease, but developed inflammatory brain lesions in his occipital lobe and midbrain (bottom panels). Following this diagnosis, he underwent HCT with excellent response, including improvement in his lung disease and resolution of most brain lesions.

C.



D.






Figure E1C, E1D. Mutations in *LRBA* in patient S14.01, father S14.02, and mother S14.03

C. The paternal allele is an intronic deletion of 4bp, at *LRBA* c.8349+4_8349+7del. The mutation leads to transcriptional deletion of *LRBA* exon 56 (197bp) and premature stop at codon 2755 of 2864, validated by Sanger sequencing of cDNA and RT-PCR of RNA from whole blood and from lymphoblast cell lines (LCLs) of the patient and his father.

D. The maternal allele is a genomic deletion of at least 2347bp, leading to transcriptional deletion of exons 18-19 (202bp) and premature stop at codon 725 of 2864, validated as for panel C.



Figure E2**Figure E2. *JAK1* triplication in patient S170**

A. Copy number on chr 1 of DNA from patient S170 normalized to other patients on the same run.

B. Alignment of *JAK1* mutant transcripts with in-tandem duplication spanning exons 2-5.


C. The mutant transcript is stable in patient lymphoblast RNA with or without treatment with puromycin to inhibit nonsense mediated decay

D. The mutant transcript is specific to mutant *JAK1* and not present in controls with normal *JAK1*

Figure E3**A.****B.****Figure E3. *TOM1* c.366+2T>C, yielding two mutant transcripts in patient S15.**

A. In RNA from patient's blood, *TOM1* c.366+2T>C results in partial retention of intron 4 leading to a 318bp message insertion and a stop at codon 192 of 493, in about 5% of transcripts from the mutant allele; and a cryptic donor splice at *TOM1* c.297 in exon 4 resulting in a 69bp message deletion (del aa 100-122 within VHS domain involved in vesicular trafficking) in about 35% of transcripts from the mutant allele. *TOM1* transcripts resulting in intronic retention are predicted to undergo degradation by nonsense-mediated decay, so that a fraction of mutant message remains undetected in blood-based RNA.

B. RT PCR of *TOM1* c.153-476 (324bp, exons 3-5), demonstrating full-length transcript, mutant transcript with retained intron 4, and mutant transcript with cryptic splice. Relative intensities of these transcripts were 0.77 (full length), 0.02 (retained intron 4), and 0.21 (cryptic splice at c.297). Intensities of RT-PCR products corresponded to proportions of TOPO TA clones: 27 of 33 clones (0.72) had full-length transcript, 1 of 33 clones had retained intron 4 (0.03), and 5 of 33 clones (0.15) were from the *TOM1* c.297 cryptic splice.

Figure E4**Figure E4. *POLAI* c.4243+5G>A in patient S114**

A. In RNA isolated from PBMCs of the patient, the mutant transcript is deleted for exon 36 (97bp), leading to a premature stop at codon 1385 of 1463.

B. RT-PCR of a segment extending from *POLAI* exon 34 to the 3'UTR demonstrates aberrant splicing from the patient compared to controls.

Table EI: Genes included in the panel

Gene	Genomic position (hg19)	Gene OMIM ID
<i>ACD</i>	chr11:6633996-6640692	609377
<i>ACP5</i>	chr19:11685474-11689823	171640
<i>ADA</i>	chr20:43248159-43280399	608958
<i>ADA2/CECRI</i>	chr22:17,659,680-17,700,325	607575
<i>ADAM17</i>	chr2:9628614-9695949	603639
<i>ADAR</i>	chr1:154554532-154580724	146920
<i>AICDA</i>	chr12:8754761-8765463	605257
<i>AIM2</i>	chr1:159032274-159046647	604578
<i>AIRE</i>	chr21:45705720-45718102	607358
<i>AP1S3</i>	chr2:224620046-224702319	615781
<i>AP3B1</i>	chr5:77298149-77590579	603401
<i>AP3D1</i>	chr19:2100986-2151556	607246
<i>ARPC1B</i>	chr7:98972297-98992424	604223
<i>ATG16L1</i>	chr2:234160216-234204320	610767
<i>ATM</i>	chr11:108093558-108239826	607585
<i>ATP11C</i>	chrX:138808504-138914447	300516
<i>ATP6AP1</i>	chrX:153656977-153664863	300197
<i>B2M</i>	chr15:45003684-45010357	109700
<i>BACH2</i>	chr6:90636246-91006627	605394
<i>BANK1</i>	chr4:102711763-102995969	610292
<i>BCL10</i>	chr1:85731458-85742587	603517
<i>BCL11B</i>	chr14:99635623-99738050	606558
<i>BCL2L1</i>	chr2:111878490-111926022	603827
<i>BLK</i>	chr8:11351520-11422108	191305
<i>BLM</i>	chr15:91260557-91358692	604610
<i>BLNK</i>	chr10:97951454-98031333	604515
<i>BLOC1S6</i>	chr15:45879757-45901914	604310
<i>BRAF</i>	chr7:140433811-140624564	164757
<i>BTB</i>	chrX:100604434-100641212	300300
<i>CIQA</i>	chr1:22962998-22966175	120550
<i>CIQB</i>	chr1:22979473-22988130	120570
<i>CIQC</i>	chr1:22970109-22974604	120575
<i>CIR</i>	chr12:7187512-7245043	613785
<i>CIS</i>	chr12:7167964-7178336	120580
<i>C2</i>	chr6:31895253-31913451	613927

<i>C3</i>	chr19:6677845-6720693	120700
<i>C4A</i>	chr6:31949833-31970457	120810
<i>C4B</i>	chr6:31982571-32003195	120820
<i>C5</i>	chr9:123714612-123812554	120900
<i>C6</i>	chr5:41142247-41213695	217050
<i>C7</i>	chr5:40909353-40984742	217070
<i>C8A</i>	chr1:57320442-57383894	120950
<i>C8B</i>	chr1:57394882-57431813	120960
<i>C8G</i>	chr9:139839697-139841426	120930
<i>C9</i>	chr5:39284245-39364662	120940
<i>CARD11</i>	chr7:2945708-3083579	607210
<i>CARD14</i>	chr17:78152306-78183130	607211
<i>CARD9</i>	chr9:139258407-139268133	607212
<i>CASP10</i>	chr2:202047620-202086383	601762
<i>CASP8</i>	chr2:202098165-202152434	601763
<i>CCBE1</i>	chr18:57098170-57364644	612753
<i>CCR7</i>	chr17:38710020-38721736	600242
<i>CD19</i>	chr16:28943259-28950668	107265
<i>CD247</i>	chr1:167399876-167487847	186780
<i>CD27</i>	chr12:6554050-6560884	186711
<i>CD28</i>	chr2:204571197-204603635	186760
<i>CD36</i>	chr7:80267831-80308593	173510
<i>CD38</i>	chr4:15779887-15854866	107270
<i>CD3D</i>	chr11:118209788-118213459	186790
<i>CD3E</i>	chr11:118175294-118186890	186830
<i>CD3G</i>	chr11:118215058-118224497	186740
<i>CD40</i>	chr20:44746892-44758384	109535
<i>CD40LG</i>	chrX:135730335-135742549	300386
<i>CD46</i>	chr1:207925382-207968861	120920
<i>CD55</i>	chr1:207494816-207534311	125240
<i>CD59</i>	chr11:33724555-33758025	107271
<i>CD70</i>	chr19:6585849-6591163	602840
<i>CD79A</i>	chr19:42381189-42385439	112205
<i>CD79B</i>	chr17:62006095-62009714	147245
<i>CD80</i>	chr3:119243139-119278481	112203
<i>CD81</i>	chr11:2398546-2418649	186845
<i>CD86</i>	chr3:121774208-121839990	601020
<i>CD8A</i>	chr2:87011727-87018837	186910
<i>CDCA7</i>	chr2:174219560-174233718	609937
<i>CEBPE</i>	chr14:23586514-23588820	600749

<i>CFB</i>	chr6:31913720-31919861	138470
<i>CFD</i>	chr19:859658-863569	134350
<i>CFH</i>	chr1:196621007-196716634	134370
<i>CFHR1</i>	chr1:196788860-196801319	134371
<i>CFHR2</i>	chr1:196912897-196928356	600889
<i>CFHR3</i>	chr1:196743929-196763203	605336
<i>CFHR4</i>	chr1:196857143-196887843	605337
<i>CFHR5</i>	chr1:196946666-196978804	608593
<i>CFI</i>	chr4:110661847-110723381	217030
<i>CFLAR</i>	chr2:201980876-202037411	603599
<i>CFP</i>	chrX:47483611-47489704	300383
<i>CHD7</i>	chr8:61591323-61780587	608892
<i>CHUK</i>	chr10:101948054-101989367	600664
<i>CIB1</i>	chr15:90773476-90777279	602293
<i>CIITA</i>	chr16:10971054-11018840	600005
<i>CISH</i>	chr3:50643884-50649262	602441
<i>CLPB</i>	chr11:72003468-72145728	616254
<i>COG6</i>	chr13:40229763-40326765	606977
<i>COL7A1</i>	chr3:48601505-48632593	120120
<i>COLEC11</i>	chr2:3642421-3692234	612502
<i>COPA</i>	chr1:160258376-160313354	601924
<i>CORO1A</i>	chr16:30194730-30200397	605000
<i>CR2</i>	chr1:207627644-207663240	120650
<i>CSF2RA</i>	chrX:1,387,693-1,428,828	306250
<i>CSF3R</i>	chr1:36931643-36948915	138971
<i>CTC1</i>	chr17:8128138-8151413	613129
<i>CTLA4</i>	chr2:204732510-204738683	123890
<i>CTPS1</i>	chr1:41444970-41478237	123860
<i>CTSC</i>	chr11:88026759-88070955	602365
<i>CXCR4</i>	chr2:136871918-136873805	162643
<i>CYBA</i>	chr16:88709696-88717492	608508
<i>CYBB</i>	chrX:37639269-37672714	300481
<i>CYLD</i>	chr16:50775960-50835846	605018
<i>DBR1</i>	chr3:137879829-137893791	607024
<i>DCLRE1B</i>	chr1:114447914-114456708	609683
<i>DCLRE1C</i>	chr10:14938795-14996900	605988
<i>DEPTOR</i>	chr8:120885894-121063157	612974
<i>DKC1</i>	chrX:153991016-154005964	300126
<i>DNASE1L3</i>	chr3:58178352-58196730	602244
<i>DNMT3B</i>	chr20:31350190-31397162	602900

<i>DOCK2</i>	chr5:169064250-169510386	603122
<i>DOCK8</i>	chr9:214000-466000	611432
<i>ELANE</i>	chr19:852208-856246	130130
<i>ENTPD1</i>	chr10:97515672-97637023	601752
<i>EPG5</i>	chr18:43427573-43547305	615068
<i>ERAP1</i>	chr5:96096513-96143892	606832
<i>ERAP2</i>	chr5:96211642-96255420	609497
<i>ERBIN</i>	chr5:65222381-65376851	606944
<i>ERCC6L2</i>	chr9:98637899-98780735	615667
<i>F12</i>	chr5:176829138-176836577	610619
<i>FAAP24</i>	chr19:33463122-33468401	610884
<i>FADD</i>	chr11:70049268-70053508	602457
<i>FAS</i>	chr10:90750315-90776818	134637
<i>FASLG</i>	chr1:172628147-172636013	134638
<i>FAT1</i>	chr4:187508936-187644987	600976
<i>FCGR1A</i>	chr1:149754249-149764074	146760
<i>FCGR2A</i>	chr1:161475204-161489360	146790
<i>FCGR2B</i>	chr1:161632904-161648444	604590
<i>FCGR3A</i>	chr1:161511548-161519893	146740
<i>FCGR3B</i>	chr1:161592985-161601252	610665
<i>FCGRT</i>	chr19:50015535-50029685	601437
<i>FCN3</i>	chr1:27695600-27701343	604973
<i>FERMT1</i>	chr20:6055491-6104191	607900
<i>FERMT3</i>	chr11:63974151-63991363	607901
<i>FLG</i>	chr1:152274650-152297679	135940
<i>FOS</i>	chr14:75745480-75748937	164810
<i>FOXN1</i>	chr17:26850350-26866100	600838
<i>FOXP3</i>	chrX:49105900-49122200	300292
<i>FPR1</i>	chr19:52249022-52255150	136537
<i>FUT2</i>	chr19:49199227-49209191	182100
<i>FYN</i>	chr6:111981534-112194655	137025
<i>G6PC3</i>	chr17:42148097-42153712	611045
<i>G6PD</i>	chrX:153759604-153775233	305900
<i>GATA2</i>	chr3:128197150-128213000	137295
<i>GFII</i>	chr1:92940317-92952433	600871
<i>GIMAP5</i>	chr7:150434435-150440737	608086
<i>GINSI</i>	chr20:25388318-25429191	610608
<i>GRB2</i>	chr17:73314156-73401789	108355
<i>GUCY2C</i>	chr12:14765565-14849519	601330
<i>HAVCR2</i>	chr5:156512842-156536248	606652

<i>HAXI</i>	chr1:154245038-154248351	605998
<i>HELLS</i>	chr10:96305523-96361856	603946
<i>HIF1A</i>	chr14:62162118-62214977	603348
<i>HPS1</i>	chr10:100175954-100206720	604982
<i>HPS4</i>	chr22:26846847-26879829	606682
<i>HPS6</i>	chr10:103825123-103827795	607522
<i>ICOS</i>	chr2:204801470-204826300	604558
<i>IFIH1</i>	chr2:163123588-163175218	606951
<i>IFNAR1</i>	chr21:34697213-34732129	107450
<i>IFNAR2</i>	chr21:34602199-34636818	602376
<i>IFNGR1</i>	chr6:137518620-137540567	107470
<i>IFNGR2</i>	chr21:34775201-34809828	147569
<i>IGHM</i>	chr14:106,320,448-106,322,322	147020
<i>IGLL1</i>	chr22:23915311-23922495	146770
<i>IKBKB</i>	chr8:42128819-42190171	603258
<i>IKBKG</i>	chrX:153775561-153793261	300248
<i>IKZF1</i>	chr7:50344264-50472799	603023
<i>IKZF2</i>	chr2:213864407-214015058	606234
<i>IKZF3</i>	chr17:37913967-38020441	606221
<i>IKZF4</i>	chr12:56414688-56432219	606239
<i>IKZF5</i>	chr10:124750321-124768203	606238
<i>IL10</i>	chr1:206940947-206945839	124092
<i>IL10RA</i>	chr11:117857105-117872198	146933
<i>IL10RB</i>	chr21:34638664-34669539	123889
<i>IL12B</i>	chr5:158741790-158757481	161561
<i>IL12RB1</i>	chr19:18169804-18197813	601604
<i>IL12RB2</i>	chr1:67773046-67862583	601642
<i>IL17A</i>	chr6:52051184-52055436	603149
<i>IL17B</i>	chr5:148753829-148758838	604627
<i>IL17C</i>	chr16:88705000-88706882	604628
<i>IL17F</i>	chr6:52101483-52109298	606496
<i>IL17RA</i>	chr22:17565848-17596584	605461
<i>IL17RC</i>	chr3:9958757-9975305	610925
<i>IL18RAP</i>	chr2:103035249-103069025	604509
<i>IL1RN</i>	chr2:113885137-113891593	147679
<i>IL21</i>	chr4:123533782-123542212	605384
<i>IL21R</i>	chr16:27438578-27463363	605383
<i>IL23R</i>	chr1:67632168-67725662	607562
<i>IL2RA</i>	chr10:6052656-6104333	147730
<i>IL2RG</i>	chrX:70327150-70331481	308380

<i>IL36RN</i>	chr2:113816684-113822321	605507
<i>IL6ST</i>	chr5:55230922-55290821	600694
<i>IL7R</i>	chr5:35856976-35880000	146661
<i>INO80</i>	chr15:41271077-41408444	610169
<i>IRAK1</i>	chrX:153275956-153285342	300283
<i>IRAK4</i>	chr12:44152746-44183346	606883
<i>IRF1</i>	chr5:131817300-131826465	147575
<i>IRF2</i>	chr4:185308875-185395726	147576
<i>IRF2BP2</i>	chr1:234740014-234745271	615332
<i>IRF3</i>	chr19:50162825-50169132	603734
<i>IRF4</i>	chr6:391738-411443	601900
<i>IRF5</i>	chr7:128578270-128590096	607218
<i>IRF7</i>	chr11:612554-615999	605047
<i>IRF8</i>	chr16:85931050-85956212	601565
<i>IRGM</i>	chr5:150226084-150281964	608212
<i>ISG15</i>	chr1:948846-949920	147571
<i>ITCH</i>	chr20:32951040-33099578	606409
<i>ITGA3</i>	chr17:48133331-48167849	605025
<i>ITGAE</i>	chr17:3617918-3704537	604682
<i>ITGAM</i>	chr16:31271287-31344213	120980
<i>ITGB2</i>	chr21:46305867-46340965	600065
<i>ITK</i>	chr5:156607906-156682109	186973
<i>ITPKB</i>	chr1:226819390-226926876	147522
<i>JAGN1</i>	chr3:9932270-9936033	616012
<i>JAK1</i>	chr1:65298905-65432252	147795
<i>JAK2</i>	chr9:4985244-5128183	147796
<i>JAK3</i>	chr19:17935590-17958841	600173
<i>JUN</i>	chr1:59246462-59249785	165160
<i>JUNB</i>	chr19:12902309-12904125	165161
<i>KDM6A</i>	chrX:44732420-44971857	300128
<i>KMT2D</i>	chr12:49411750-49450000	602113
<i>KRAS</i>	chr12:25357722-25403865	190070
<i>LAG3</i>	chr12:6881669-6887621	153337
<i>LAMTOR2</i>	chr1:156024516-156028301	610389
<i>LAT</i>	chr16:28996386-29002104	602354
<i>LCK</i>	chr1:32739711-32751768	153390
<i>LIG1</i>	chr19:48618701-48673860	126391
<i>LIG4</i>	chr13:108859789-108867130	601837
<i>LPIN2</i>	chr18:2916991-3011945	605519
<i>LRBA</i>	chr4:151185810-151936419	606453

<i>LRRC8A</i>	chr9:131644780-131680318	608360
<i>LYN</i>	chr8:56792385-56925006	165120
<i>LYST</i>	chr1:235824330-236030227	606897
<i>MAGT1</i>	chrX:77081860-77151065	300715
<i>MAL</i>	chr2:95691399-95719737	188860
<i>MALT1</i>	chr18:56338617-56417371	604860
<i>MAP2K1</i>	chr15:66679210-66783882	176872
<i>MAP3K14</i>	chr17:43340485-43394430	604655
<i>MAPK8</i>	chr10:49514681-49647403	601158
<i>MASP1</i>	chr3:186933872-187009810	600521
<i>MASP2</i>	chr1:11086579-11107296	605102
<i>MCM10</i>	chr10:13203553-13253104	609357
<i>MCM4</i>	chr8:48872762-48890720	602638
<i>MEFV</i>	chr16:3292027-3306627	608107
<i>MOGS</i>	chr2:74688183-74692537	601336
<i>MPO</i>	chr17:56347216-56358296	606989
<i>MS4A1</i>	chr11:60223281-60238225	112210
<i>MSH5</i>	chr6:31707724-31730455	603382
<i>MSH6</i>	chr2:48010220-48034092	600678
<i>MSN</i>	chrX:64887510-64961793	309845
<i>MTHFD1</i>	chr14:64854758-64926725	172460
<i>MVK</i>	chr12:110011499-110035075	251170
<i>MYD88</i>	chr3:38179968-38184513	602170
<i>MYO5A</i>	chr15:52599479-52821247	160777
<i>MYO5B</i>	chr18:47349155-47721451	606540
<i>MYSM1</i>	chr1:59120410-59165747	612176
<i>NBN</i>	chr8:90945563-90996899	602667
<i>NCF1</i>	chr7:74188308-74203720	608512
<i>NCF2</i>	chr1:183524696-183559739	608515
<i>NCF4</i>	chr22:37257029-37274059	601488
<i>NEIL3</i>	chr4:178230990-178284092	608934
<i>NFAT5</i>	chr16:69599868-69738569	604708
<i>NFATC1</i>	chr18:77155771-77289323	600489
<i>NFATC2</i>	chr20:50003493-50159258	600490
<i>NFATC3</i>	chr16:68119268-68263162	602698
<i>NFATC4</i>	chr14:24836116-24848810	602699
<i>NFKB1</i>	chr4:103422485-103538459	164011
<i>NFKB2</i>	chr10:104154334-104162286	164012
<i>NFKBIA</i>	chr14:35870715-35873960	164008
<i>NFKBIB</i>	chr19:39390569-39399534	604496

<i>NFKBID</i>	chr19:36378853-36391564	
<i>NFKBIZ</i>	chr3:101568357-101579869	608004
<i>NHEJ1</i>	chr2:219940045-220025587	611290
<i>NHP2</i>	chr5:177576463-177580961	606470
<i>NLRC4</i>	chr2:32449517-32490812	606831
<i>NLRP1</i>	chr17:5417437-5487832	606636
<i>NLRP12</i>	chr19:54296837-54327657	609648
<i>NLRP3</i>	chr1:247581350-247612410	606416
<i>NLRP7</i>	chr19:55434876-55458873	609661
<i>NOD2</i>	chr16:50731049-50766988	605956
<i>NOP10</i>	chr15:34633916-34635362	606471
<i>NRAS</i>	chr1:115247084-115259515	164790
<i>NSMCE3</i>	chr15:29560352-29562020	608243
<i>NT5E</i>	chr6:86159301-86205509	129190
<i>ORAI1</i>	chr12:122064454-122079946	610277
<i>OTULIN</i>	chr5:14664753-14699959	615712
<i>PARN</i>	chr16:14529556-14724128	604212
<i>PAX1</i>	chr20:21686296-21699124	167411
<i>PAX5</i>	chr9:36833271-37034476	167414
<i>PDCD1</i>	chr2:242792032-242801058	600244
<i>PGM3</i>	chr6:83874591-83903655	172100
<i>PIAS1</i>	chr15:68346913-68483802	603566
<i>PIAS2</i>	chr18:44395672-44497495	603567
<i>PIAS3</i>	chr1:145575987-145586546	605987
<i>PIAS4</i>	chr19:4007595-4039384	605989
<i>PIK3CD</i>	chr1:9711789-9789172	602839
<i>PIK3CG</i>	chr7:106505722-106549423	601232
<i>PIK3R1</i>	chr5:67511583-67597649	171833
<i>PLCG2</i>	chr16:81812862-81996298	600220
<i>PMM2</i>	chr16:8891669-8943194	601785
<i>PMS2</i>	chr7:6010555-6048737	600259
<i>PNP</i>	chr14:20937537-20946165	164050
<i>POLA1</i>	chrX:24711949-25015103	312040
<i>POLE</i>	chr12:133200347-133264110	174762
<i>POLE2</i>	chr14:50110269-50155098	602670
<i>POLR3A</i>	chr10:79734906-79789298	614258
<i>POMP</i>	chr13:29233140-29253094	613386
<i>PRF1</i>	chr10:72357103-72362531	170280
<i>PRKCD</i>	chr3:53195222-53226733	176977
<i>PRKCQ</i>	chr10:6469104-6622263	600448

<i>PRKDC</i>	chr8:48685668-48872743	600899
<i>PSMA3</i>	chr14:58711522-58738727	176843
<i>PSMB10</i>	chr16:67968406-67970780	176847
<i>PSMB4</i>	chr1:151372040-151374412	602177
<i>PSMB8</i>	chr6:32808493-32812712	177046
<i>PSMB9</i>	chr6:32821937-32827628	177045
<i>PSME1</i>	chr14:24605366-24608176	600654
<i>PSME2</i>	chr14:24612573-24615855	602161
<i>PSTPIP1</i>	chr15:77287425-77329816	606347
<i>PTEN</i>	chr10:89623194-89731687	601728
<i>PTPN11</i>	chr12:112856701-112947722	601728
<i>PTPN22</i>	chr1:114356432-114414381	600716
<i>PTPRC</i>	chr1:198608097-198726605	151460
<i>RAB27A</i>	chr15:55495163-55562592	603868
<i>RAC2</i>	chr22:37621300-37640339	602049
<i>RAG1</i>	chr11:36589562-36601312	179615
<i>RAG2</i>	chr11:36613492-36619829	179616
<i>RASGRP1</i>	chr15:38780301-38857007	603962
<i>RBCK1</i>	chr20:388693-412783	610924
<i>RC3H1</i>	chr1:173900221-173962210	609424
<i>REL</i>	chr2:61108629-61155306	164910
<i>RELA</i>	chr11:65421066-65430443	164014
<i>RELB</i>	chr19:45504706-45541456	604758
<i>RFX5</i>	chr1:151313115-151319769	601863
<i>RFXANK</i>	chr19:19303007-19312678	603200
<i>RFXAP</i>	chr13:37393338-37403740	601861
<i>RHOH</i>	chr4:40198526-40246384	602037
<i>RIT1</i>	chr1:155867598-155880706	609591
<i>RLTPR</i>	chr16:67679029-67691472	610859
<i>RMRP</i>	chr9:35,657,748-35,658,015	157660
<i>RNASEH2A</i>	chr19:12917427-12924462	606034
<i>RNASEH2B</i>	chr13:51483813-51530901	610326
<i>RNASEH2C</i>	chr11:65485143-65488409	610330
<i>RNF168</i>	chr3:196195653-196230639	612688
<i>RNF31</i>	chr14:24616658-24629870	612487
<i>RNU4ATAC</i>	chr2:122,288,441-122,288,598	601428
<i>RORC</i>	chr1:151778546-151804348	602943
<i>RPSA</i>	chr3:39448179-39454033	150370
<i>RTKL1</i>	chr20:62289162-62327606	608833
<i>SAMD9</i>	chr7:92728825-92747336	610456

<i>SAMD9L</i>	chr7:92759366-92777701	611170
<i>SAMHD1</i>	chr20:35520226-35580246	606754
<i>SBDS</i>	chr7:66452689-66460588	607444
<i>SBNO2</i>	chr19:1107632-1174282	615729
<i>SEC61A1</i>	chr3:127771211-127790526	609213
<i>SEMA3E</i>	chr7:82993221-83278479	608166
<i>SERPING1</i>	chr11:57365026-57382326	606860
<i>SH2B3</i>	chr12:111843751-111889427	605093
<i>SH2D1A</i>	chrX:123480131-123507010	300490
<i>SH3BP2</i>	chr4:2820540-2842823	602104
<i>SHARPIN</i>	chr8:145153535-145159140	611885
<i>SKIV2L</i>	chr6:31926580-31937532	600478
<i>SLC11A1</i>	chr2:219246751-219261617	600266
<i>SLC29A3</i>	chr10:73079009-73123147	612373
<i>SLC35C1</i>	chr11:45826640-45834567	605881
<i>SLC37A4</i>	chr11:118895060-118901616	602671
<i>SLC46A1</i>	chr17:26721660-26733230	611672
<i>SLC7A7</i>	chr14:23242430-23285107	603593
<i>SMARCA1</i>	chr2:217277136-217347776	606622
<i>SMARCD2</i>	chr17:61909440-61920351	601736
<i>SOCS1</i>	chr16:11348273-11350039	603597
<i>SOCS2</i>	chr12:93963597-93970521	605117
<i>SOCS3</i>	chr17:76352857-76356160	604176
<i>SOCS4</i>	chr14:55493843-55516207	616337
<i>SOCS5</i>	chr2:46926098-46989927	607094
<i>SOCS6</i>	chr18:67956136-67997434	605118
<i>SOCS7</i>	chr17:36508006-36561846	608788
<i>SP110</i>	chr2:231033633-231084827	604457
<i>SPINK5</i>	chr5:147443534-147516925	605010
<i>SPPL2A</i>	chr15:50999729-51057910	608238
<i>STAT1</i>	chr2:191833761-191878976	600555
<i>STAT2</i>	chr12:56735380-56754037	600556
<i>STAT3</i>	chr17:40465342-40540513	102582
<i>STAT4</i>	chr2:191894301-192016322	600558
<i>STAT5A</i>	chr17:40439565-40463960	601511
<i>STAT5B</i>	chr17:40351194-40428424	604260
<i>STAT6</i>	chr12:57489186-57505196	601512
<i>STIM1</i>	chr11:3876932-4114440	605921
<i>STK4</i>	chr20:43595114-43708618	604965
<i>STN1</i>	chr10:105637315-105678045	613128

<i>STX11</i>	chr6:144471653-144513076	605014
<i>STXBP2</i>	chr19:7701986-7712760	601717
<i>SYK</i>	chr9:93563961-93660842	600085
<i>TALDO1</i>	chr11:747431-765024	602063
<i>TAP1</i>	chr6:32812985-32821748	170260
<i>TAP2</i>	chr6:32793186-32806547	170261
<i>TAPBP</i>	chr6:33267470-33282164	601962
<i>TAZ</i>	chrX:153639853-153650065	300394
<i>TBC1D8B</i>	chrX:106045918-106119380	301027
<i>TBK1</i>	chr12:64845839-64895899	604834
<i>TCF3</i>	chr19:1609288-1652328	147141
<i>TCN2</i>	chr22:31003069-31023047	613441
<i>TERC</i>	chr3:169,482,398-169,482,848	602322
<i>TERT</i>	chr5:1253281-1295162	187270
<i>TFRC</i>	chr3:195776154-195808961	190010
<i>TGFBR1</i>	chr9:101867370-101916474	190181
<i>TGFBR2</i>	chr3:30647993-30735634	190182
<i>THBD</i>	chr20:23026269-23030301	188040
<i>TICAM1</i>	chr19:4815935-4831754	607601
<i>TIGIT</i>	chr3:114012832-114029135	612859
<i>TINF2</i>	chr14:24708848-24711880	604319
<i>TIRAP</i>	chr11:126152981-126163071	606252
<i>TLR3</i>	chr4:186990308-187006252	603029
<i>TLR4</i>	chr9:120466452-120479769	603030
<i>TLR7</i>	chrX:12885201-12908480	300365
<i>TLR9</i>	chr3:52255095-52260179	605474
<i>TMC6</i>	chr17:76108998-76124875	605828
<i>TMC8</i>	chr17:76126858-76139049	605829
<i>TMEM173</i>	chr5:138855112-138862375	612374
<i>TNFAIP3</i>	chr6:138188324-138204451	191163
<i>TNFRSF11A</i>	chr18:59992519-60054943	603499
<i>TNFRSF13B</i>	chr17:16842397-16875402	604907
<i>TNFRSF13C</i>	chr22:42321035-42322821	606269
<i>TNFRSF18</i>	chr1:1138887-1142089	603905
<i>TNFRSF1A</i>	chr12:6437922-6451283	191190
<i>TNFRSF4</i>	chr1:1146705-1149548	600315
<i>TNFSF12</i>	chr17:7452374-7461207	602695
<i>TNFSF4</i>	chr1:173152869-173176452	603594
<i>TOM1</i>	chr22:35695796-35743987	604700
<i>TPP2</i>	chr13:103249285-103332308	190470

<i>TRAF1</i>	chr9:123664670-123689173	601711
<i>TRAF2</i>	chr9:139780964-139821067	601895
<i>TRAF3</i>	chr14:103243815-103377837	601896
<i>TRAF3IP2</i>	chr6:111880142-111927154	607043
<i>TRAF6</i>	chr11:36505316-36531863	602355
<i>TREX1</i>	chr3:48506918-48509044	606609
<i>TRNT1</i>	chr3:3168599-3190707	612907
<i>TTC37</i>	chr5:94799598-94890709	614589
<i>TTC7A</i>	chr2:47168312-47303275	609332
<i>TYK2</i>	chr19:10461203-10491248	176941
<i>UNC13D</i>	chr17:73823305-73840798	608897
<i>UNC93B1</i>	chr11:67758570-67771595	608204
<i>UNG</i>	chr12:109535922-109548798	191525
<i>USB1</i>	chr16:58035276-58055527	613276
<i>USP18</i>	chr22:18632757-18660164	607057
<i>VPS13B</i>	chr8:100025493-100889814	607817
<i>VPS45</i>	chr1:150039349-150117505	610035
<i>WAS</i>	chrX:48542185-48549818	300392
<i>WASF2</i>	chr1:27730729-27816698	300392
<i>WDR1</i>	chr4:10075962-10118573	604734
<i>WIPF1</i>	chr2:175424301-175499307	602357
<i>XIAP</i>	chrX:122994016-123047829	300079
<i>ZAP70</i>	chr2:98330030-98356323	176947
<i>ZBTB1</i>	chr14:64971291-64991669	616578
<i>ZBTB24</i>	chr6:109783718-109804440	614064
<i>ZBTB46</i>	chr20:62375020-62436856	614639
<i>ZNF341</i>	chr20:32319565-32380075	618269

Table EII. Recommendations for therapy, gene-by-gene, for patients with genetic diagnoses

Gene	N*	Recommendations for therapy
<i>AIRE</i>	1	Consider azathioprine and rituximab. Recommend pneumococcal vaccination; pulmonary, thyroid, parathyroid, liver screening labs and imaging
<i>BACH2</i>	1	Consider pulmonary and immunoglobulin level screening
<i>BCL11B</i>	2	Neurologic screening. Consider HCT
<i>CARD11</i>	4	No clear therapeutic or screening recommendations
<i>CARD14</i>	2	Consider TNF-alpha inhibitors and IL12/IL23 inhibitors. Unlikely amenable to HCT
<i>CTLA4</i>	4	Consider abatacept, sirolimus, or hct. Recommend regular screening for malignancy
<i>IRF2BP2</i>	1	Recommend screening for pulmonary and GI disease, and for antibody defects
<i>ITCH</i>	1	No clear therapeutic or screening recommendations
<i>JAK1</i>	3	Consider JAK inhibitors
<i>KMT2D</i>	1	Recommend screening for antibody defects and cardiac defects
<i>LRBA</i>	4	Consider abatacept, sirolimus, or HCT. Recommend regular screening for malignancy.
<i>MYO5B</i>	1	Unlikely amenable to HCT
<i>NFKB1</i>	1	Recommend screening for renal, thyroid, pulmonary, and hematologic disease. Also recommend screening for malignancy.
<i>NLRC4</i>	1	Consider recombinant IL-18-binding protein (in trials)
<i>POLA1</i>	2	Recommend regular ophthalmologic screening exams
<i>POMP</i>	1	No clear therapeutic or screening recommendations
<i>RAG1</i>	2	Consider HCT. Recommend screening for renal, thyroid, pulmonary, and hematologic disease
<i>SH2D1A</i>	1	Consider HCT. Recommend regular screening for malignancy
<i>SKIV2L</i>	1	Unlikely amenable to HCT
<i>STAT1</i>	2	Consider JAK inhibitors. Consider screening for cranial aneurysms
<i>STAT3</i>	4	Consider JAK inhibitors, IL-6 inhibitors, or HCT. Consider screening for pulmonary disease and malignancy.
<i>TNFAIP3</i>	2	TNF-alpha inhibitors
<i>TNFRSF6</i> <i>/FAS</i>	1	Consider sirolimus. Recommend regular screening for malignancy.
<i>TNFRSF13B</i>	1	No clear therapeutic or screening recommendations
<i>TOM1</i>	1	Consider pulmonary screening
<i>TTC37</i>	2	Unlikely amenable to HCT
<i>XIAP</i>	1	Consider recombinant IL-18-binding protein (in trials) and HCT

*N: number of patients in this study with a damaging mutation in the indicated gene

Table I. Patient characteristics

	N	Proportion
Age at referral		
0 - 2 y	40	0.33
2 - 4 y	26	0.21
5 - 9 y	18	0.15
10 - 14 y	13	0.11
15+ y	17	0.14
not recorded	9	0.07
Total	123	1.00
Gender		
Male	94	0.76
Female	29	0.24
Total	123	1.00
Ancestry		
Caucasian, not Hispanic	78	0.63
Caucasian, Hispanic	24	0.20
East Asian	9	0.07
African American	5	0.04
Middle East/West Asian	4	0.03
Central/South Asian	2	0.02
Native American	1	0.01
Total	123	1.00
Major reported clinical features		

Enteropathy	69	0.56
Dermatitis	30	0.24
Autoimmunity	45	0.37
Immunodeficiency; recurrent infections	37	0.30
"IPEX" only	29	0.24
No information recorded	11	0.09

Table II. Genetic diagnoses with phenotypic classifications of the International Union of Immunological Societies (IUIS)

Patient	Age	Gender	Gene	AI / II*	"IPEX-like" gene**	Inh^	Clinical features
IUIS: Diseases of immune dysregulation							
S048	11 y	M	<i>AIRE</i>	AI	no	AR	Addison's disease and recurrent oral thrush
S093	22 m	F	<i>BACH2</i>	AI, II	no	AD	Chronic diarrhea
S092	12 y	M	<i>CTLA4</i>	AI	yes	AD	Enteropathy, total parenteral nutrition dependence, alopecia totalis; HSCT
S175	9 y	M	<i>CTLA4</i>	AI	yes	AD	Onset 3y. Watery diarrhea, type 1 diabetes, anti-thyroid antibodies, hemolytic anemia, thrombocytopenia, lymphadenopathy, splenomegaly, alopecia; HSCT
S190	16 y	M	<i>CTLA4</i>	AI	yes	AD	Colitis, eczema, hypothyroidism, common variable immunodeficiency, cytopenias
S018	11 y	F	<i>CTLA4, CD28, CASP8</i>	AI	yes	AD	Autoimmune enteropathy, eczema, interstitial pneumonitis, seizures, DD, pulmonary hypertension, vitiligo, thrombocytopenia, pan-hypogammaglobulinemia; recurrent infections including esophageal candidiasis, otitis media, and sinusitis
S184	13 y	M	<i>FAS/TNFRSF6</i>	AI, II	no	AD	Enteropathy with villous atrophy from 1y, eczema, type 1 diabetes, alopecia, recurrent severe infections, short stature, seizures. Low IgA and IgG levels, and B cell lymphopenia
S071	3 y	M	<i>ITCH</i>	AI, II	yes	AR	Autoimmune thyroid disease, FTT, DD, chronic secretory and bloody diarrhea, alopecia, hemolytic anemia, eczema, recurrent fungal and bacterial infections. Low IgM levels; positive pANCA and anti-smooth muscle antibodies
S066	7 m	F	<i>JAK1</i>	AI, II	no	AD	Dysmorphisms, enteropathy, hypogammaglobulinemia, failure to thrive, hepatitis, and decreased FOXP3 T-cells. Died from sepsis. Five siblings died in infancy.
S067	2 y	M	<i>JAK1</i>	AI, II	no	AD	Enteropathy and immunodeficiency, with decreased FOXP3 expression.

S170	4 m	M	<i>JAK1</i>	AI, II	no	AD	Exfoliative dermatitis, enteropathy, anemia, thrombocytopenia, neutropenia, hepatosplenomegaly.
S014	4 y	M	<i>LRBA</i>	AI	yes	AR	Type 1 diabetes, autoimmune enteropathy, autism, lymphoma
S045	14 y	M	<i>LRBA</i>	AI	yes	AR	Diarrhea from age 3 mo., malabsorption, type 1 diabetes, esophageal candidiasis, and delayed puberty. Died age 16y of intestinal adenocarcinoma
S129	17 y	F	<i>LRBA</i>	AI	yes	AR	Hypothyroidism, inflammatory bowel disease, hepatosplenomegaly, hemolytic anemia, and hypogammaglobulinemia
S088	10 y	M	<i>LRBA</i>	AI	yes	AR	Early onset type 1 diabetes mellitus, autoimmune cytopenias, arthritis, interstitial lung disease, autoimmune enteropathy, uveitis, eczema, failure to thrive, recurrent warts, inflammatory brain lesions. Hypogammaglobulinemia, low T-regulatory cells
S123	11 y	M	<i>SH2D1A</i>	AI, II	no	AD	Alopecia totalis, neutropenia, recurrent infections, mucositis, dermatitis, colitis; HSCT
S041	6 m	M	<i>STAT3</i>	AI, II	yes	AD	Chronic diarrhea, severe eczema, recurrent respiratory infections and developmental delay; HSCT
S068	8 y	M	<i>STAT3</i>	AI, II	yes	AD	"IPEX"
S112	9 y	M	<i>STAT3</i>	AI, II	yes	AD	Recurrent infections, type 1 diabetes, immune thrombocytopenic purpura, hypothyroidism, short stature, and mild hypogammaglobulinemia
S108	20 m	M	<i>XIAP</i>	AI, II	no	XR	Severe malabsorption, failure to thrive
IUIS: Autoinflammatory disorders							
S030	4 m	M	<i>CARD14</i>	II	no	AD	Severe eczema, multiple food allergies, enteropathy
S055	3 y	F	<i>CARD14</i>	II	no	AD	Colitis
S098	1 m	M	<i>NLR4</i>	II	no	AD	Intractable diarrhea, distended bowel with mucosal autolysis and erosions, severe pulmonary congestion and hemorrhage, ascites, viral meningitis
S102	2 y	M	<i>POLA1</i>	II	no	XR	Immune dysregulation

S114	ni	M	<i>POLA1</i>	II	no	XR	Unknown
S160	2 m	M	<i>POMP</i>	II	no	AD	Enteropathy, dermatitis, pulmonary nodules, recurrent respiratory infections, mild thrombocytopenia, and elevated IgE
S027	3 y	M	<i>TNFAIP3</i>	AI, II	no	AD	Watery diarrhea, eczema, failure to thrive, autoantibodies to thyroid (without frank thyroiditis), elevated IgE.
S087	12 y	F	<i>TNFAIP3</i>	AI, II	no	AD	"IPEX"
IUIS: Predominantly antibody deficiency							
S125	4 y	F	<i>IRF2BP2</i>	AI, II	no	AD	Chronic diarrhea, severe eczema, anemia, failure to thrive, fevers, short stature, recurrent infections, cataracts, hypodontia, hypotrichosis alopecia, hypogammaglobulinemia
S043	6 y	M	<i>TACI</i>	AI	no	AD	Eczema, enteropathy with complete villous atrophy; HSCT
IUIS: Combined immunodeficiency with associated features							
S025	6 y	M	<i>BCL11B</i>	AI, II	no	AD	Failure to thrive, nutritional deficiencies, chronic emesis, pyloric stenosis, focal villous blunting of duodenum
S029	1 mo.	M	<i>BCL11B</i>	AI, II	no	AD	Severe dermatitis
S040	6 m	M	<i>CARD11</i>	AI, II	yes	AD	Watery diarrhea with villous atrophy, eczema, type 1 diabetes, failure to thrive, alopecia areata, skin tags, club foot
S046	8 y	M	<i>CARD11</i>	AI, II	yes	AD	Enteropathy, severe atopic dermatitis, failure to thrive, high IgE levels
S178	11 m	M	<i>CARD11</i>	AI, II	yes	AD	Unknown
S179	1 m	F	<i>CARD11</i>	AI, II	yes	AD	"IPEX"
S100	25 y	F	<i>KMT2D</i>	AI	no	AD	Short stature, high arched palate; autoimmune disease, enteropathy. Small intestine transplant.
S024	4 m	M	<i>NFKB1</i>	AI	no	AD	"IPEX"

S021	16 y	F	<i>RAG1</i>	AI	no	AR	Hypogammaglobulinemia, aplastic anemia, autoimmune enteropathy. Died at age 16y of fungal infection
S090	2 m	M	<i>RAG1</i>	AI	no	AR	"IPEX"
S182	4 m	M	<i>SKIV2L</i>	II	no	AR	Severe enteropathy, failure to thrive, total parenteral nutrition dependence, psoriatic-type rash, watery diarrhea with villous atrophy, dilated aortic root, developmental delay. Died age 4y.
S097	2 y	M	<i>STAT3</i>	AI, II	yes	AD	Chronic enteropathy and chronic liver disease.
S070	7 m	M	<i>TTC37</i>	II	yes	AR	Failure to thrive, small triangular face, sparse hair. Death not related to immune disease.
S186	5 y	F	<i>TTC37</i>	II	yes	AR	Enteropathy with villous atrophy from age 1 y, eczema, recurrent severe upper respiratory infections and gastrointestinal infections, hemolytic anemia, thrombocytopenia, alopecia, developmental delay, trichorrhexis nodosa
IUIS: Defects in intrinsic and innate immunity							
S120	3 y	M	<i>STAT1</i>	AI, II	yes	AD	"IPEX"
S103	19 y	M	<i>STAT1</i>	AI, II	yes	AD	Enteropathy, dermatitis, failure to thrive, autoimmune hemolytic anemia, recurrent infections including oropharyngeal candidiasis and herpes zoster, hypogammaglobulinemia with low T-regulatory cells
IUIS: Not included in IUIS categories							
SDH	19 y	M	<i>MYO5B</i>	-	no	AR	Enteropathy and failure to thrive; reduced expression of FOXP3 and of CD25. Two previously deceased siblings.
S015	2 y	M	<i>TOM1</i>	II	no	AD	Congenital autoimmune enteropathy, exocrine pancreatic insufficiency, failure to thrive, hepatitis, atopic dermatitis, pityriasis alba, hypogammaglobulinemia, lymphopenia
*Role of the gene in adaptive immunity (AI), innate immunity (II), or both **Genes previously associated with diagnoses of "IPEX-like" syndrome ^Inheritance of the phenotype: autosomal dominant (AD), autosomal recessive (AR), or X-linked recessive (XR). Complete genotypes are indicated in Table S2.							

Table III. Variant alleles and interpretations

Pt	Gene	Mutation	hg19 position	Type / PPH2 / gerp	Clin Var	This study	Geno-type	Functional consequence of mutation; evidence for causality	gnomAD **
S048	<i>AIRE</i>	c.967_979del, p.D323fs	chr21:45711063	LoF	P	P	cpd het*	Well-documented pathogenic mutation (PMID: 9837820)	138
S048	<i>AIRE</i>	c.1249insC, p.L417fs	chr21:45713024	LoF	P/LP	P	cpd het*	Well-documented pathogenic mutation (PMID: 10677297)	5
S093	<i>BACH2</i>	c.C1586T, p.A529V	chr6:90660239	1.00 / 5.2	ni	LP	het	Completely conserved site. Reduced FOXP3 expression in patient cells, consistent with BACH2 haploinsufficiency (PMID: 28530713)	5
S025	<i>BCL11B</i>	c.C779T, p.T260M	chr14:99642394	1.00 / 3.8	ni	LP	het	Destroys completely conserved phosphorylation site	9
S029	<i>BCL11B</i>	c.C2421G, p.N607K	chr14:99640752	1.00 / 3.7	P	P	het	Well-documented pathogenic mutation (PMID: 27959755)	0
S040	<i>CARD11</i>	c.C1483T, p.P495S	chr7:2974122	0.58^ / 5.2	ni	LP	het	Highly conserved site; enhanced TCR-induced NFkB activation (PMID:30170123)	3
S046	<i>CARD11</i>	c.C88T, p.R30W	chr7:2987341	1.00 / 4.5	P/VUS	LP	het	Completely conserved site; co-segregates with combined immunodeficiency (PMID: 28826773); leads to reduced secretion of IFN-gamma and IL-2 (PMID: 28826773)	0
S178	<i>CARD11</i>	c.G2510A, p.R837Q	chr7:2959006	1.00 / 4.1	ni	LP	het	Predict loss of donor splice, transcriptional deletion of exon 18 and stop at codon 764	0

S179	<i>CARD11</i>	c.G1670A, p.R557H	chr7:2968316	1.00 / 4.9	VUS	VUS	het	Highly conserved site; same mutation reported in another immunodeficiency patient, but no functional effect detected by saturation genome editing (PMID: 33202260)	4
S030	<i>CARD14</i>	c.G669C, p.Q223H	chr17:78158031	1.00 / na	ni	LP	het	Completely conserved site; phenotype is excellent fit	4
S055	<i>CARD14</i>	c.C605T, p.S202L	chr17:78157967	1.00 / 3.6	ni	VUS	het	Highly conserved site; no functional information	4
S092	<i>CTLA4</i>	c.G118A; p.V40M	chr2:204735317	1.00 / 5.3	LP/ VUS	LP	het	Completely conserved site in homodimerization domain; reported in patients with primary immunodeficiency (PMID: 29077208, 30048690)	0
S175	<i>CTLA4</i>	c.523dupT; p.L174fs	chr2:204736165	LoF	ni	P	het	Truncating mutation; haploinsufficiency is pathogenic (PMID: 25329329)	0
S190	<i>CTLA4</i>	c.C208T; p.R70W	chr2:204735407	1.00 / 4.3	P	P	het	One of original CTLA4 pathogenic mutations; decreased CTLA4 T-regulatory cells (PMID: 25329329)	0
S018	<i>CTLA4, CD28, CASP8</i>	2.83MB deletion	chr2:201994549-204824394 del	LoF	ni	P	het	Complete deletion of gene	0
S125	<i>IRF2BP2</i>	c.1606insTTT, p.Q536delinsX	chr1:234743040	LoF	ni	P	het	<i>De novo</i> truncating mutation at codon 536 of 587; we confirmed experimentally that the mutant message is stable	0
S071	<i>ITCH</i>	c.393dupA; p.T131fs	chr20:33001602	LoF	ni	P	homoz	Truncating mutation. Original <i>ITCH</i> pathogenic mutation, cosegregating with disease (PMID: 20170897)	0

S066	<i>JAK1</i>	c.T2414A, p.F805Y	chr1:65307274	1.00 / 4.6	ni	LP	het	Private mutation at completely conserved site in kinase domain; family includes 6 children with JAK1 phenotype	0
S067	<i>JAK1</i>	c.C1901A, p.A634D	chr1:65312418	1.00 / 3.9	LP	P	het	Activating somatic mutation (PMID: 20167706); not previously observed in germline	0
S170	<i>JAK1</i>	25kb triplication	chr1:65337211-65362210	inframe tripl	ni	LP	het	Tandem triplication of exons 2-5, encoding aa 1-151 of membrane-binding FREM domain, stable mutant message experimentally confirmed (Fig S2)	0
S100	<i>KMT2D</i>	c.4132-1G>A	chr12:49441853	inframe del	ni	P	het	Clinically dx as Kabuki. Transcriptional loss of exon 14, encoding aa 1378-1412, stable mutant message experimentally confirmed	0
S014	<i>LRBA</i>	2347bp del	chr4:151792136-151794482	LoF	ni	P	cpd het*	Transcriptional loss of exons 18-19 (202 bp), stop codon 725 of 2864; maternal allele; experimentally confirmed (Fig S1)	0
S014	<i>LRBA</i>	c.8349+4_8349+7del	chr4:151203595	LoF	ni	P	cpd het*	Transcriptional loss of exon 56 (197 bp), stop codon 2755 of 2864; paternal allele; experimentally confirmed (Fig S1)	0
S045	<i>LRBA</i>	c.C6640T, p.R2214X	chr4:151392836	LoF	P/LP	P	homoz	Known pathogenic mutation (PMID: 29867916)	1
S129	<i>LRBA</i>	c.C5047T, p.R1683X	chr4:151749456	LoF	P	P	cpd het*	Known pathogenic mutation (PMID: 22608502)	0

S129	<i>LRBA</i>	>277bp deletion	chr4:151935548-151935825 (min del)	LoF	ni	P	cpd het*	Genomic deletion of exon 2 including translation start; experimentally confirmed (Fig S1)	0
S088	<i>LRBA</i>	79 kb deletion	chr4:151599677-151678661 del	inframe del	ni	P	cpd het*	Deletion of exons 36-37, encoding aa 1882-1974, region highly conserved across all BEACH proteins; maternal allele; experimentally confirmed (Fig S1)	0
S088	<i>LRBA</i>	c.G2736A, p.W912X	chr4:151788853	LoF	ni	P	cpd het*	Truncating mutation; experimentally confirmed as paternal allele (Fig S1)	0
SBDH	<i>MYO5B</i>	c.G946A, p.G316R	chr18:47511088	0.99 / 5.5	VUS	LP	homoz	Predict loss of donor splice site and transcriptional deletion of exon 8, encoding aa 280-355 of myosin motor domain; same mutation in patient with microvillus atrophy (PMID: 21206382)	18
S024	<i>NFKB1</i>	c.A2494C, p.N832H	chr4:103533665	1.00 / 5.1	ni	LP	het	Completely conserved site in death domain, critical to programmed cell death (PMID: 10786798). Also predicted loss of splice enhancer and transcriptional deletion of exon 22 (173bp), stop at codon 829 of 969.	0
S098	<i>NLRC4</i>	c.T1022C, p.V341A	chr2:32475911	0.99 / 3.3	P	P	het	Documented gain of function, pathogenic mutation (PMID: 25217960)	0
S114	<i>POLAI</i>	c.4243+5G>A	chrX:24948671	LoF	ni	LP	hemiz	Splice effect experimentally confirmed, transcriptional deletion of exon 36 (97bp), stop at codon 1385 of 1463.	2 hemiz

S102	<i>POLAI</i>	c.G304T, p.D102Y	chrX:24722562	1.00 / 2.2	ni	VUS	hemiz	Basepair completely conserved; predict loss of exonic splice enhancer, transcriptional deletion exon 4 encoding aa 83-109, no RNA available to validate splice effect	0 hemiz
S160	<i>POMP</i>	c.342del14, p.F114fs	chr13:29246553	LoF	P	P	het	Original pathogenic mutation for <i>POMP</i> , escapes NMD (PMID: 29805043)	0
S021	<i>RAG1</i>	c.A1336G, p.N446D	chr11:36596190	0.99 / 5.6	ni	LP	cpd het*	Completely conserved in DNA-binding domain. Missense at A444V is pathogenic.	0
S021	<i>RAG1</i>	c.C2095T, p.R699W	chr11:36596949	1.00 / na	P	P	cpd het*	Documented pathogenic mutation with reduced T and B-cells (PMID:20956421)	4
S090	<i>RAG1</i>	c.G2147A, p.R716Q	chr11:36597001	1.00 / 6.1	LP	LP	cpd het*	Completely conserved site in RAG1 domain	1
S090	<i>RAG1</i>	c.G2924A, p.R975Q	chr11:36597778	1.00 / 5.6	P	P	cpd het*	Multiple reports as damaging (PMID:20956421); impairs recombination activity (PMID: 18768869)	12
S123	<i>SH2D1A</i>	c.T160A, p.Y54N	chrX:123499633	1.00 / 4.8	ni	LP	hemiz	Completely conserved site in SH2 domain; Y54C protein has reduced stability and binding affinity (PMID: 14674764)	0
S182	<i>SKIV2L</i>	c.A1907G, p.H636R	chr6:31932055	1.00 / 6.0	ni	LP	cpd het*	Completely conserved site in helicase domain; cpd het with truncating mutation; good fit to phenotype	2
S182	<i>SKIV2L</i>	c.C3187T, p.R1063X	chr6:31936654	LoF	ni	LP	cpd het*	Truncating mutation	33

S120	<i>STAT1</i>	c.T1627C, p.C543R	chr2:191845351	0.99 / 5.1	ni	VUS	het	Completely conserved site in STAT-binding domain consistent with autosomal dominant immunodeficiency; no sample available for functional analysis and no DNA available from parents to test if <i>de novo</i>	0
S103	<i>STAT1</i>	c.C820T, p.R274W	chr2:191859911	1.00 / 5.7	ni	LP	het	R274G is known gain of function allele, increases STAT1 dependence on cytokines (PMID:21727188)	0
S041	<i>STAT3</i>	c.G1032C, p.Q344H	chr17:40485708	0.99 / 4.2	P	P	het	Documented gain of function pathogenic mutation (PMID: 25359994)	0
S068	<i>STAT3</i>	c.C2144T, p.T715M	chr17:40469200	1.00 / 5.0	P	P	het	Documented gain of function pathogenic mutation (PMID: 25359994)	0
S097	<i>STAT3</i>	c.G1909A, p.V637M	chr17:40474492	1.00 / 3.7	P	P	het	Documented gain of function pathogenic mutation (PMID:21727188)	0
S112	<i>STAT3</i>	c.T937C, p.F313L	chr17:40485928	0.99 / 5.6	ni	LP	het	Completely conserved site in STAT-alpha domain; private allele; good fit to phenotype	0
S043	<i>TACI/ TNFRSF13B</i>	c.G311A, p.C104Y	chr17:16852186	1.00 / 5.0	LP	LP	het	Completely conserved site; documented in families and patients with CVID (PMID:18981294, 27123465, 22884984); C104R leads to reduced immunoglobulin production (PMID: 21458042, 20889194)	33
S027	<i>TNFAIP3</i>	c.1127delC, p.S376fs	chr6:138199709	LoF	ni	P	het	Truncating mutation; haploinsufficiency is a causal mechanism for TNFAIP3 syndromes (PMID: 26642243)	0

S087	<i>TNFAIP3</i>	c.G2300A, p.C767Y	chr6:138202383	1.00 / 5.7	ni	LP	het	Completely conserved site at critical cysteine in zinc finger; haploinsufficiency is causal mechanism for TNFAIP3 syndromes (PMID: 26642243)	0
S184	<i>TNFRSF6 / FAS</i>	c.A260G, p.E87G	chr10:90767520	1.00 / 3.1	ni	LP	het	Completely conserved site at critical turn in disulfide binding domain	0
S015	<i>TOM1</i>	c.267+2T>C	chr22:35719172	LoF / inframe del	ni	P	het	Splice mutation yielding two mutant transcripts: (1) intron 4 retained, leading to premature stop; (2) cryptic donor splice leading to deletion of aa 20-152 of vesicular trafficking domain. Experimentally confirmed (Fig S3)	4
S070	<i>TTC37</i>	c.C409T, p.R137X	chr5:94876528	LoF	P	P	homoz	Documented pathogenic mutation	2
S186	<i>TTC37</i>	c.994+1G>A	chr5:94864704	inframe del	ni	LP	cpd het*	Predict loss of donor splice site, transcript deletion of exon 12 and aa 298-331	1
S186	<i>TTC37</i>	c.402+2T>G	chr5:94877007	LoF	ni	P	cpd het*	Predict loss of donor splice site and transcriptional deletion of exon 7 and stop at codon 142 of 1564	0
S108	<i>XIAP</i>	c.949del11, p.W317fs	chrX:123022540	LoF	ni	P	hemiz	Truncating mutation	0

* All paired alleles of compound heterozygous (cpd het) genotypes were experimentally confirmed to be in trans in the patient

** All gnomAD entries are heterozygotes unless otherwise indicated

^ Completely conserved as proline through mammals; no species has serine as reference sequence

ni: no information on ClinVar; PP2: polyphen-2 score; gerp: gerp score; LoF: loss of function

P: pathogenic; LP: likely pathogenic; VUS: unknown significance, warranting further evaluation